Innovage Holding Corp. SEC Filings

Form 4 filing summary – KeyCorp (KEY), 07/01/2025: Director Barbara R. Snyder converted 35,955 deferred shares (transaction code M) into an equal number of common shares. The conversion increased her directly held common-share position to 71,632 shares. No open-market purchase or sale price was reported because the shares derive from KeyCorp’s Directors’ Deferred Share Sub-Plan, where each deferred share is economically equivalent to a common share. Following the transaction, Snyder still holds 177,901 deferred shares that remain subject to the plan. The filing also notes that direct ownership totals include roughly 175 common shares obtained through the June 2025 dividend-reinvestment program, and deferred-share holdings include about 2,765 dividend-equivalent units accrued during the same period. As there was no disposition of shares and the transaction merely settles a long-standing equity award, the impact on KeyCorp’s public float and insider sentiment is modest.

Dyadic International, Inc. (Nasdaq: DYAI) filed a Form 8-K on 2 July 2025 to disclose a branding update. In 30 days the company will begin operating under the business name “Dyadic Applied BioSolutions.” The filing clarifies that the legal corporate name remains “Dyadic International, Inc.,” the DYAI ticker is unchanged, and the company will continue to trade on the Nasdaq Stock Market. The disclosure is provided under Item 7.01 (Regulation FD) and is furnished—not filed—thereby carrying no Section 18 liability and no direct impact on financial statements. No financial data, operational revisions, or strategic transactions are included; the report solely communicates the forthcoming DBA designation and furnishes the related press release as Exhibit 99.1.

InnovAge Holding Corp. (INNV) filed a Form 4 disclosing that director Edward M. Kennedy Jr. received 25,316 Restricted Stock Units (RSUs) on July 1, 2025. The award was recorded at a purchase price of $0 because RSUs are equity compensation rather than open-market purchases.

The RSUs will vest in full on June 30, 2026, provided the director remains in service through that date. Upon settlement, the units will convert into an equivalent number of common shares. Following the grant, Kennedy’s direct beneficial ownership totals 68,157 shares of InnovAge common stock.

No sales, option exercises, derivative positions, or other transactions were reported. The filing therefore reflects a routine equity-compensation grant that modestly increases insider alignment but does not involve immediate cash inflows, earnings information, or strategic developments.

Dillard’s, Inc. (DDS) Form 4 filing dated 07/02/2025 discloses a modest open-market purchase by long-time insider Drue Matheny, Executive Vice President and Director. On 06/30/2025 Matheny acquired 19 Class A common shares at $413.32 each, increasing her direct holding to 403,904 shares. She also continues to hold 36,648 shares through the company retirement plan and 9,821 shares indirectly (7,300 as trustee of the GST Trust and 2,521 held by her spouse). No derivative transactions were reported.

The purchase represents less than 0.005% of her direct ownership and is immaterial to DDS’s 17 million share float, yet any insider buying—particularly by a senior executive—may be interpreted as a confidence signal. There were no sales, option exercises, or 10b5-1 plan indications, and the filing confirms her continuing status as both officer and director.

Form 4 filing overview: On 06/30/2025, MAIA Biotechnology, Inc. (ticker MAIA) granted director Cristian Luput a package of stock options under the company’s 2021 Equity Incentive Plan.

• Options granted: 21,350 options to purchase common shares.
• Exercise price: $1.80 per share.
• Vesting schedule: 100% vested immediately on the grant date.
• Expiration: 06/30/2035 (10-year term).
• Post-transaction holdings: Luput now holds 21,350 derivative securities directly.

No non-derivative share transactions were reported, and the filing was made individually by the director. The grant represents routine equity compensation designed to align director incentives with shareholder value, but it modestly increases the company’s fully diluted share count.

On 30 June 2025, Wintrust Financial Corp. (WTFC) director Brian A. Kenney reported the acquisition of 420 common shares under the company’s Director’s Deferred Fee and Stock Plan, as disclosed in a Form 4 filing. The shares were credited at a price of $112.46, increasing Kenney’s direct beneficial ownership to 11,214 WTFC shares. The transaction is coded “A,” indicating an award rather than an open-market purchase, and no derivative securities were involved. While routine in nature, the filing slightly increases insider ownership and may be viewed as a signal of continued alignment between the director and shareholder interests.